特集「臓器移植と悪性腫瘍」
悪性腫瘍の既往・併存レシピエントに対する肝移植の適応
キーワード:
pre-transplant malignancy,
liver transplantation,
malignant tumor,
de novo malignancy,
immunosuppressant
2024 年 59 巻 2 号 p. 119-128
詳細
2024 年 59 巻 2 号 p. 119-128
The increase in liver transplant (LT) recipients’ age and improved survival rates have led to more patients with pre-transplant malignancies (PTMs). Common risk factors, like obesity and alcohol use, often link nonhepatic cancer with chronic liver diseases. Immunosuppressive therapy in LT recipients raises the risk of post-transplant cancer recurrence, affecting survival rates. Although PTM’s impact is well-studied in kidney transplants, data for LT is limited. Patients with cirrhosis and cancer have outcomes influenced by cirrhosis severity and chemotherapy’s impact on liver function. This study examines LT eligibility and required waiting period for PTM patients, focusing on cancer type and treatment history. Comprehensive cancer history is essential for evaluating LT eligibility. Future research should gather extensive data on PTM’s effect on post-LT outcomes, identifying recurrence risk factors to improve management and survival.
